Blau Syndrome / Early-Onset Sarcoidosis
Blau syndrome is a rare inherited autoinflammatory disorder in which non-necrotizing granulomas form in several organs. It is caused by mutations in the NOD2 gene (formerly CARD15) that leave the NOD2 protein overactive, keeping the body in a state of ongoing systemic inflammation.
At Haute-Derma, we manage Blau syndrome as a condition that needs close teamwork between dermatology, ophthalmology and rheumatology. Our main goal is to bring granulomatous inflammation under control early, before it causes irreversible damage, above all vision loss and joint deformity.
Our Approach to Treating Blau Syndrome
Our specialists at Haute-Derma focus on dampening the NF-κB pathway that the NOD2 mutation switches on. Blau syndrome usually begins very early (before age 4) with characteristic skin findings, and this is the window when treatment can best protect a child's eyesight and mobility.
We use anti-TNF-alpha biologic therapies, which work well to shrink granulomas and maintain lasting remission. Every patient at Haute-Derma receives a personalized monitoring plan so that any sign of eye or joint inflammation is dealt with promptly.
Our Blau syndrome care pathway includes:
- NOD2 gene sequencing to confirm the genetic diagnosis.
- Targeted biologic therapy (anti-TNF or anti-IL-1).
- A dedicated vision-protection program run with leading ophthalmologists.
How We Diagnose Blau Syndrome at Haute-Derma
Our diagnosis at Haute-Derma rests on the clinical triad, confirmed by genetic testing:
- Recognizing the skin lesions: small reddish-brown or pale pink papules, resembling goosebumps, scattered over the trunk and limbs.
- Assessing the joints: looking for synovitis that causes persistent joint swelling, usually without the severe pain seen in rheumatoid arthritis.
- Eye screening: regular dilated eye exams to catch panuveitis early, as it is the most dangerous complication of Blau syndrome.
- Granuloma biopsy: histology looking for non-caseating granulomas in the skin or synovium.
- NOD2 mutation analysis: the gold standard for separating inherited Blau syndrome from ordinary sarcoidosis.
How Is Blau Syndrome Treated at Haute-Derma?
Our treatment plan at Haute-Derma aims to suppress granulomatous inflammation across every affected organ:
- Anti-TNF-alpha therapy (adalimumab, infliximab): our first choice at Haute-Derma when corticosteroids are not enough. These drugs control uveitis well and help prevent joint fibrosis.
- Methotrexate or other immunosuppressants: help lower the corticosteroid dose and keep skin and joint disease stable over the long term.
- Managing acute uveitis: specialized eye drops and local injections to prevent corneal scarring and cataracts.
- Rehabilitative physical therapy: helps children keep their joints moving and prevents contractures and deformity in the long run.
- Family genetic counseling: because the condition is inherited in a dominant pattern, Haute-Derma offers screening for family members to identify those who do not yet have obvious symptoms.
